Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: Report on five cases

Archives of Dermatological Research

Volumn 300, Issue 3, 2008, Pages 101-105

  Mössner, Rotraut ^a   Thaci, Diamant ^b   Mohr, Johannes ^a   Pätzold, Sylvie ^b   Bertsch, Hans Peter ^a   Krüger, Ullrich ^a   Reich, Kristian ^c  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c DERMATOLOGIKUM HAMBURG   (Germany)

Author keywords

Antagonist; Infliximab; Psoriasis; Pustulosis; TNF

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; PSORALEN;

ADULT; AGED; ARTICLE; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG WITHDRAWAL; FEMALE; HUMAN; IMMUNOMODULATION; MALE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PUSTULOSIS PALMOPLANTARIS; PUVA; SKIN MANIFESTATION; TREATMENT WITHDRAWAL; ULTRAVIOLET A RADIATION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; DERMATOLOGIC AGENTS; FEMALE; HUMANS; MALE; PSORIASIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 39949085766     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-008-0831-8     Document Type: Article

References (23)

1. Adams DR, Buckel T, Sceppa JA (2006) Infliximab associated new-onset psoriasis. J Drugs Dermatol 5:178-179
2. Asumalahti K, Ameen M, Suomela S, Hagforsen E, Michaelsson G, Evans J, Munro M, Veal C, Allen M, Leman J, David BA, Kirby B, Connolly M, Griffiths CE, Trembath RC, Kere J, Saarialho-Kere U, Barker JN (2003) Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Invest Dermatol 120:627-632
3. Benoit S, Toksoy A, Brocker EB, Gillitzer R, Goebeler M (2004) Treatment of recalcitrant pustular psoriasis with infliximab: effective reduction of chemokine expression. Br J Dermatol 150:1009-1012
4. Beuthien W, Mellinghoff HU, von Kempis J (2004) Skin reaction to adalimumab. Arthritis Rheum 50:1690-1692
5. Carey W, Glazer S, Gottlieb AB, Lebwohl M, Leonardi C, Menter A, Papp K, Rundle AC, Toth D (2006) Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 54:S171-S181
6. de Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP (2007) Psoriasis and pustular dermatitis triggered by TNF-{alpha} inhibitors in patients with rheumatologic conditions. Arch Dermatol 143:223-231
7. Fiorentino DF (2007) The Yin and Yang of TNF-{alpha} inhibition. Arch.Dermatol 143:233-236
8. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL (2005) Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 7:R666-R676
9. Gottlieb AB, Matheson RT, Lowe N, Krueger GG, Kang S, Goffe BS, Gaspari AA, Ling M, Weinstein GD, Nayak A, Gordon KB, Zitnik R (2003) A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 139:1627-1632
10. Kary S, Worm M, Audring H, Huscher D, Renelt M, Sorensen H, Stander E, Maass U, Lee H, Sterry W, Burmester GR (2006) New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 65:405-407
11. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E (2005) Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? Br J Dermatol 153:1243-1244
12. Mössner R, Kingo K, Kleensang A, Kruger U, Konig IR, Silm H, Westphal GA, Reich K (2005) Association of TNF -238 and -308 promoter polymorphisms with psoriasis vulgaris and psoriatic arthritis but not with pustulosis palmoplantaris. J Invest Dermatol 124:282-284
13. Newland MR, Weinstein A, Kerdel F (2002) Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type. Int J Dermatol 41:449-452
14. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367-1374
15. Schmick K, Grabbe J (2004) Recalcitrant, generalized pustular psoriasis: rapid and lasting therapeutic response to antitumour necrosis factor-alpha antibody (infliximab). Br J Dermatol 150:367
16. Sfikakis PP, Iliopoulos A, Elezoglou A, Kittas C, Stratigos A (2005) Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 52:2513-2518
17. Starmans-Kool MJ, Peeters HR, Houben HH (2005) Pustular skin lesions in patients treated with infliximab: report of two cases. Rheumatol Int 25:550-552
18. Thurber M, Feasel A, Stroehlein J, Hymes SR (2004) Pustular psoriasis induced by infliximab. J Drugs Dermatol 3:439-440
19. Wegscheider BJ, El Shabrawi L, Weger M, Ardjomand N, Hermann J, Aberer E, El Shabrawi Y (2007) Adverse skin reactions to infliximab in the treatment of intraocular inflammation. Eye 21:547-549
20. Mrowietz U, Elder JT, Barker J (2006) The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 298:309-319
21. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke WH, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels HM, Orzechowski HD, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B (2007) German evidence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 299:111-138
22. Papp KA (2006) The long-term efficacy and safety of new biological therapies for psoriasis. Arch.Dermatol.Res 298(1):7-15
23. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M (2006) Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 298:321-328